ic9-gd2 t cell
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01822652)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ic9-gd2 t cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01822652 | Phase 1 | Aug 1, 2013 | Baylor University, Methodist Cancer Center, Houston, Texas, National Cancer Institute (NCI), The EVAN Foundation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| The EVAN Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1